940 shaares
Myloid-reducing monoclonal antibodies for patients with Alzheimer have harmful risks, such as cerebral edema, hemorrhage, serious adverse events, and death, according to a new study.
Myloid-reducing monoclonal antibodies for patients with Alzheimer have harmful risks, such as cerebral edema, hemorrhage, serious adverse events, and death, according to a new study.
